Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma.

Ishihara, Hiroki; Fukuda, Hironori; Yoshida, Kazuhiko; Hashimoto, Yasunobu; Kondo, Tsunenori; Takagi, Toshio

Ishihara, Hiroki; Fukuda, Hironori; Yoshida, Kazuhiko; Hashimoto, Yasunobu; Kondo, Tsunenori; Takagi, Toshio.

Afiliação

Ishihara H; Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Fukuda H; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Yoshida K; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Hashimoto Y; Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.
Kondo T; Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Int J Urol ; 30(2): 240-242, 2023 02.

Article em En | MEDLINE | ID: mdl-36397731

Assuntos

Neoplasias Encefálicas; Carcinoma de Células Renais; Neoplasias Renais; Humanos; Carcinoma de Células Renais/patologia; Inibidores de Checkpoint Imunológico/efeitos adversos; Neoplasias Renais/patologia; Nivolumabe/efeitos adversos; Neoplasias Encefálicas/tratamento farmacológico

Palavras-chave

RCC; brain metastases; immunotherapy; ipilimumab; nivolumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Carcinoma de Células Renais / Neoplasias Renais Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google